Nivolumab (NIVO) + ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced NSCLC (aNSCLC) in CheckMate 227 part 1: Efficacy by KRAS, STK11, and KEAP1 mutation status Meeting Abstract
| Authors: | Ramalingam, S. S.; Balli, D.; Ciuleanu, T. E.; Pluzanski, A.; Lee, J. S.; Schenker, M.; Caro, R. B.; Lee, K. H.; Bartolucci, R.; Audigier-Valette, C.; Hellmann, M. D.; Paz-Ares, L. G.; Reck, M.; Borghaei, H.; Brahmer, J. R.; O'Byrne, K.; Tran, P.; Spires, T.; Geese, W. J.; Agrawal, S. |
| Abstract Title: | Nivolumab (NIVO) + ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced NSCLC (aNSCLC) in CheckMate 227 part 1: Efficacy by KRAS, STK11, and KEAP1 mutation status |
| Meeting Title: | ESMO Immuno-Oncology Congress 2021 |
| Journal Title: | Annals of Oncology |
| Volume: | 32 |
| Issue: | Suppl. 7 |
| Meeting Dates: | 2021 Dec 8-11 |
| Meeting Location: | Virtual |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2021-12-01 |
| Start Page: | S1375 |
| End Page: | S1376 |
| Language: | English |
| ACCESSION: | WOS:000731051400005 |
| DOI: | 10.1016/j.annonc.2021.10.020 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 40 -- Source: Wos |
